Literature DB >> 25913846

Muscle weakness in children with neurofibromatosis type 1.

Kayla M D Cornett1,2, Kathryn N North3,4, Kristy J Rose1,2, Joshua Burns1,2,3,5.   

Abstract

AIM: To investigate if children with neurofibromatosis type 1 (NF1) have reduced muscle strength compared with children with typical development.
METHOD: Maximal isometric strength of 15 upper and lower limb muscle groups was evaluated in 30 children with NF1 (16 males, 14 females; aged 4-16y) and 30 age-, sex-, height-, and weight-matched controls using hand-held dynamometry by a single evaluator. Both the left and right sides were assessed.
RESULTS: Children with NF1 were significantly weaker than children with typical development across all 15 muscle groups assessed (p<0.05). Apart from elbow flexion, there were no differences between the left and right sides (p>0.05). Magnitude of differences between the children with NF1 compared with the controls ranged from 3% to 43%. Males and females were equally affected.
INTERPRETATION: This study shows that children with NF1 have reduced muscle strength compared with children with typical development. This muscle weakness is present from the earliest stages of the disease assessed and persists throughout childhood with no sex difference. These results support recent evidence from mouse studies that NF1 is associated with a primary myopathy.
© 2015 Mac Keith Press.

Entities:  

Mesh:

Year:  2015        PMID: 25913846     DOI: 10.1111/dmcn.12777

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  4 in total

Review 1.  An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains.

Authors:  Taylor F Smith; Jessica A Kaczorowski; Maria T Acosta
Journal:  Childs Nerv Syst       Date:  2020-07-03       Impact factor: 1.475

Review 2.  The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Authors:  Amish Chinoy; Grace R Vassallo; Emma Burkitt Wright; Judith Eelloo; Siobhan West; Eileen Hupton; Paula Galloway; Amy Pilkington; Raja Padidela; M Zulf Mughal
Journal:  J Musculoskelet Neuronal Interact       Date:  2022-03-01       Impact factor: 1.864

3.  Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2.

Authors:  Srivandana Akshintala; Nashwa Khalil; Kaleb Yohay; Alona Muzikansky; Jeffrey Allen; Anna Yaffe; Andrea M Gross; Michael J Fisher; Jaishri O Blakeley; Beverly Oberlander; Miriam Pudel; Celia Engelson; Jaime Obletz; Carole Mitchell; Brigitte C Widemann; David A Stevenson; Scott R Plotkin
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

4.  L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.

Authors:  Emily R Vasiljevski; Joshua Burns; Paula Bray; Gabrielle Donlevy; Anita J Mudge; Kristi J Jones; Matthew A Summers; Andrew Biggin; Craig F Munns; Marnee J McKay; Jennifer N Baldwin; David G Little; Aaron Schindeler
Journal:  Am J Med Genet A       Date:  2021-06-21       Impact factor: 2.578

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.